[Glitazones. Profile of a new class of substances].
Janka
H U
HU
Klinikum für Innere Medizin, II. Med. Abt., Zentralkrankenhaus Bremen-Nord, Hammersbecker Str. 228, 28755 Bremen.
D000419:Albuminuria / Q000188:drug therapy; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D002839:Chromans / Q000009:adverse effects; D003577:Cytochrome P-450 Enzyme System / Q000737:chemistry*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005858:Germany; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D007527:Isoenzymes / Q000737:chemistry; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D045162:Thiazolidinediones; D000077288:Troglitazone; D014481:United States
D000924:Anticholesteremic Agents; D002839:Chromans; D007004:Hypoglycemic Agents; D007527:Isoenzymes; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D003577:Cytochrome P-450 Enzyme System; C089946:2,4-thiazolidinedione; D000077288:Troglitazone; D000077205:Pioglitazone